BiotechTube
Sonosine

Sonosine

London, United Kingdom· Est.
sonosine.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Sonosine is a private, pre-revenue deep-tech company developing a disruptive medical imaging diagnostic device called the Pulsar 1. Its core technology, Electro Magnetic Acoustics (EMA), integrates radio signals with ultrasound to provide tissue-type information that ultrasound alone cannot, aiming to offer a quicker, safer, and more affordable point-of-care alternative to modalities like MRI. The company targets the global medical imaging market with a product designed to improve the patient journey from point-of-care to diagnosis. Based in London and founded in 2017, Sonosine appears to be in the late-stage development or early commercialization phase for its first product.

Drug Delivery

Technology Platform

Electro Magnetic Acoustics (EMA) imaging technology that combines radio signals with ultrasound to reveal tissue types for improved diagnostic imaging.

Opportunities

The Pulsar 1 addresses a large gap in the market for a point-of-care imaging tool that provides tissue characterization beyond standard ultrasound, offering a quicker and more affordable alternative to MRI.
Its mobility and lower cost could enable adoption in outpatient clinics and lower-resource settings, expanding access to advanced diagnostics.

Risk Factors

Key risks include the need to clinically validate the novel EMA technology against established imaging standards, navigating complex regulatory pathways for medical devices, and overcoming commercial barriers in a market dominated by large, entrenched competitors.
Securing sufficient funding to complete development and launch is also a critical challenge.

Competitive Landscape

Sonosine competes in the large medical imaging market dominated by giants like GE, Siemens, Philips, and Canon. It positions itself against MRI (on cost, speed, and comfort) and advanced ultrasound systems (on tissue characterization capability). Its success depends on proving a unique diagnostic value proposition not met by these incumbents.

More companies in United Kingdom →